Recent Updates
Recently added Catalysts
NMRA Negative Sentiment Score: 20/100

Neumora Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; April 7, 2025 Deadline to file Lead Plaintiff Motion

Key Takeaway: Neumora Therapeutics, Inc. faces a class action lawsuit from investors who claim that the company made false statements regarding its Phase Two trial of Navacaprant. The law firm, Portnoy Law Firm, is encouraging affected investors to file a lead plaintiff motion by April 7, 2025. Allegations include the manipulation of trial data and inclusion criteria to falsely demonstrate the drug's efficacy in treating Major Depressive Disorder. Additionally, deficiencies in the trial's data, particularly related to patient demographics, have raised serious concerns.

Market Sentiment Analysis

CONCERNS & RISKS

  • Investors are encouraged to seek legal action due to alleged corporate misconduct.
  • Neumora has been accused of altering trial inclusion criteria to mislead about its drug's effectiveness.
  • Insufficient data from Phase Two trials raises concerns about the validity of outcomes.
  • The company's handling of patient demographics has also been criticized.

Full Press Release Details

Investors can contact the law firm at no cost to learn more about recovering their losses
LOS ANGELES, March 31, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Neumora Therapeutics, Inc. ("Neumora" or the "Company") (NASDAQ: NMRA) investors of a class action representing investors who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to the Offering Documents, commencing on or about September 15, 2023. Neumora investors have until April 7, 2025 to file a lead plaintiff motion.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
The complaint alleges that during the class period, Defendants made materially false or misleading statements and failed to disclose key information. Specifically, Neumora altered BlackThorn’s original Phase Two trial inclusion criteria to include patients with moderate to severe Major Depressive Disorder (MDD) in an effort to justify proceeding with its Phase Three Program and demonstrate that Navacaprant, its flagship therapeutic candidate, provided statistically significant improvement in treating MDD. Additionally, the company modified the Phase Two statistical analysis plan by introducing a prespecified analysis focused on patients with moderate to severe MDD. Furthermore, the Phase Two trials lacked sufficient data—particularly regarding patient population size and the male-to-female ratio—making it difficult to accurately predict the outcomes of the KOASTAL-1 study.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
Attorney Advertising

Tags

Frequently Asked Questions

How can Neumora investors recover their losses?

Neumora investors can contact the Portnoy Law Firm for a free evaluation and to pursue claims.

What is the deadline to file a lead plaintiff motion?

Investors have until April 7, 2025, to file a lead plaintiff motion.

What legal claims are being made against Neumora?

The complaint alleges that Neumora made misleading statements and altered trial criteria.

How can I contact attorney Lesley F. Portnoy?

You can reach Lesley F. Portnoy at 310-692-8883 or lesley@portnoylaw.com.

What is the Portnoy Law Firm's track record?

The firm has recovered over $5.5 billion for investors in corporate wrongdoing cases.

Last updated: Mar 31, 2025